Heart Matters

Host: Marius M. Hoeper A recent study explored the safety and efficacy of sotatercept on top of background pulmonary arterial hypertension (PAH) therapy. To learn more about this clinical data, Dr. Marius M. Hoeper, a Professor of Medicine and the Deputy Director of the Department of Respiratory Medicine at Hannover Medical School in Hannover, Germany, dives into the results of this trial and explores how they may impact patients with PAH.

According to the CDC, patients with familial hypercholesterolemia or patients who show signs of coronary heart disease are at an increased chance of having heart attack, stroke, and aortic stenosis due to high levels of lipoprotein(a). So how can me manage lipoprotein(a) in our patients? To discuss this, Dr. Mary Katherine Cheeley is joined by fellow ReachMD host Dr. Alan Brown, who’s also the Director of the Division of Cardiology and the Lipid Clinic at Advocate Lutheran General Hospital.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Kevin C. Maki, PhD, FNLA, CLS At the American College of Cardiology's 72nd Annual Scientific Session & Expo, cardiologists will gather to explore the latest advancements in the field. Joining us to share what you can expect to learn about statin intolerance at their upcoming session are Dr. Mary Katherine Cheeley and Dr. Kevin Maki.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Laney K. Jones, PharmD, MPH Patients with familial hypercholesterolemia (FH) are at an increased risk of developing coronary heart disease at a young age. So what’s on the horizon for using implementation science strategies in treating patients with FH? Learn more about implementation science as Dr. Mary Katherine Cheeley discusses this with Dr. Laney Jones, Associate Professor at Geisinger’s Department of Genomic Health.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Lauren Williams, MCN,RD,LD Kids with dyslipidemia don’t have much different nutritional needs than other young kids their age. However, there are a few key things to be aware of. So how can clinicians meet families where they are to improve their diet? Dive into the unique needs of youth with dyslipidemia as Dr. Mary Katherine Cheeley is joined by Lauren Williams, Class II Clinical Dietician at Cook Children’s Health System.

Host: Matthew Sorrentino, MD Guest: Luke Laffin, MD Six commonly used supplements thought to improve patients’ cholesterol may be doing more harm than good. So what do we need to know about these supplements? To walk us through the results of the SPORT trial, Dr. Matthew Sorrentino is joined by Dr. Luke Laffin, Co-Director of the Center for Blood Pressure Disorders at the Cleveland Clinic.

Host: Javed Butler, MD, MBA, MPH Guest: Scott Solomon, MD Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction (DELIVER trial) is a study designed to assess the effectiveness of SGLT2 inhibitors in patients with higher left ventricular ejection fraction. To help lead the discussion on the results of this study, Dr. Javed Butler is joined by Dr. Scott Solomon, lead study author and Director of the Clinical Trials Outcomes Center and the Edward D. Frohlich Distinguished Chair at Harvard Medical School.

Host: Ajay K. Singh, MBBS, FRCP, MBA Guest: Kirsten L. Johansen, MD Anemia in chronic kidney disease (CKD) is persistently undermanaged because current treatments have been linked with an increased risk for major cardiovascular events. They are also injectable or intravenous and definitely invasive, which no doubt limits patient acceptance. Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a novel class of small-molecule oral drugs in late-phase development and under review by the FDA that are poised to provide an alternative treatment paradigm for patients with CKD-related anemia. Physicians and other clinicians who manage patients with anemia in CKD will need to be familiar with these novel agents and the data supporting their use in appropriately selected patients.

Host: Matthew Sorrentino, MD Guest: Michael A. Solomon, MD, MBA Guest: Sean Agbor-Enoh, MD, PhD Pulmonary arterial hypertension (PAH) is a rare, and even fatal, condition that can impair the chest and lungs. But could a new blood test help us better assess disease severity and survivability in patients with PAH? To dive deeper into this topic, Dr. Matthew Sorrentino is joined by Dr. Michael Solomon and Dr. Sean Agbor-Enoh from the National Institutes of Health.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Yehuda Handelsman, MD The National Lipid Association (NLA) and the American College of Cardiology (ACC) recently provided recommendations to help us achieve optimal low-density lipoprotein (LDL) levels in statin-intolerant patients, but what other management strategies are available? Joining Dr. Charles Turck to answer this question and to give more key insights is Dr. Yehuda Handelsman, Medical Director and Principal Investigator at the Metabolic Institute of America.